Dr. Nataliya Razumilava, MD

Dr. Razumilava practices at University Hospital in Ann Arbor, Michigan.

Dr. Razumilava's NPI, 1104072438, was assigned on August 18, 2008. Dr. Razumilava holds Michigan license 4301087376.

Dr. Razumilava's primary practice is University Hospital, at 1500 E Medical Center Dr, Ann Arbor, MI 48109. The practice phone is (734) 936-4000.

Dr. Razumilava's primary practice is University Hospital in Ann Arbor, Michigan. Dr. Razumilava is also affiliated with University Hospital. The medical group on file is University of Michigan Health. Dr. Razumilava's employer is on file too: a school & student health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Razumilava practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Razumilava's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Razumilava is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Razumilava's licenses on file in 2 states: Michigan and Minnesota.

CMS data shows 30 Medicare services from Dr. Razumilava across 1 procedure code in 2024, all of them office visits, for 46 Medicare patients. Medicare paid $3,466 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 46 Medicare patients who saw Dr. Razumilava in 2024. The largest group is 65 to 74, with 22 patients. 61% of them have high blood pressure, and 52% have high cholesterol. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Razumilava's median patient age at 66, with 45% women.

In 2024, Dr. Razumilava wrote 72 Medicare Part D claims for 18 patients. 76% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $14,960 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

Dr. Razumilava accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Razumilava as offering telehealth.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 36 papers to Dr. Razumilava, published from 2010 to 2024. 2018 was the busiest year, with 4. The most frequent topics are Cholangiocarcinoma, Bile Duct Neoplasms and Bile Ducts, Intrahepatic. Dr. Razumilava has published most often in Hepatology. Dr. Razumilava's most frequent co-authors are Gregory J. Gores, MD, Jorge A. Bezerra, MD and Lewis R. Roberts, MBCHB, PhD.

CMS Open Payments shows 2 general payments to Dr. Razumilava from 1 drug or device company in 2019. Gifts make up the largest share, 67% of the total. Gilead Sciences, Inc. paid the most, $377.